A Study of TFX05-01 in Patients With Advanced Solid Tumors

NCT05434299 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: TFX05-01

Sponsor

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.